{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:37:16Z","timestamp":1790797036073,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11102-022-01259-3","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T07:06:06Z","timestamp":1661756766000},"page":"882-890","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma"],"prefix":"10.1007","volume":"25","author":[{"given":"Yaron","family":"Rudman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadar","family":"Duskin-Bitan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Masri-Iraqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Akirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9188-3894","authenticated-orcid":false,"given":"Ilan","family":"Shimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"1259_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxford) 72:377\u2013382. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03667.x","journal-title":"Clin Endocrinol (Oxford)"},{"key":"1259_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1365-2265.1994.tb02557.x","volume":"41","author":"T Mindermann","year":"1994","unstructured":"Mindermann T, Wilson CB (1994) Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxford) 41:359\u2013364. https:\/\/doi.org\/10.1111\/j.1365-2265.1994.tb02557.x","journal-title":"Clin Endocrinol (Oxford)"},{"key":"1259_CR3","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1210\/jcem.82.7.4088","volume":"82","author":"E Delgrange","year":"1997","unstructured":"Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102\u20132107. https:\/\/doi.org\/10.1210\/jcem.82.7.4088","journal-title":"J Clin Endocrinol Metab"},{"key":"1259_CR4","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.4065\/73.11.1046","volume":"73","author":"RD Calle-Rodrigue","year":"1998","unstructured":"Calle-Rodrigue RD, Giannini C, Scheithauer BW et al (1998) Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc 73:1046\u20131052. https:\/\/doi.org\/10.4065\/73.11.1046","journal-title":"Mayo Clin Proc"},{"key":"1259_CR5","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1210\/jc.2003-030979","volume":"89","author":"A Colao","year":"2004","unstructured":"Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, Zarrilli S, Lombardi G (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89:1704\u20131711. https:\/\/doi.org\/10.1210\/jc.2003-030979","journal-title":"J Clin Endocrinol Metab"},{"key":"1259_CR6","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1210\/jcem.85.9.6798","volume":"85","author":"JJ Pinzone","year":"2000","unstructured":"Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A (2000) Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 85:3053\u20133057. https:\/\/doi.org\/10.1210\/jcem.85.9.6798","journal-title":"J Clin Endocrinol Metab"},{"key":"1259_CR7","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/cen.14541","volume":"95","author":"Y Rudman","year":"2021","unstructured":"Rudman Y, Duskin-Bitan H, Manisterski Y, Pertzov B, Akirov A, Masri-Iraqi H, Shimon I (2021) Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: does size really matter? Clin Endocrinol (Oxford) 95:606\u2013617. https:\/\/doi.org\/10.1111\/cen.14541","journal-title":"Clin Endocrinol (Oxford)"},{"key":"1259_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1023\/a:1025377816769","volume":"5","author":"L Sibal","year":"2002","unstructured":"Sibal L, Ugwu P, Kendall-Taylor P, Ball SG, James RA, Pearce SH, Hall K, Quinton R (2002) Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis: II. Proportion of cases exhibiting recovery of pituitary function. Pituitary 5:243\u2013246. https:\/\/doi.org\/10.1023\/a:1025377816769","journal-title":"Pituitary"},{"key":"1259_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11102-014-0563-z","volume":"18","author":"A Tirosh","year":"2015","unstructured":"Tirosh A, Benbassat C, Lifshitz A, Shimon I (2015) Hypopituitarism patterns and prevalence among men with macroprolactinomas. Pituitary 18:108\u2013115. https:\/\/doi.org\/10.1007\/s11102-014-0563-z","journal-title":"Pituitary"},{"key":"1259_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1365-2265.2006.02461.x","volume":"64","author":"M De Rosa","year":"2006","unstructured":"De Rosa M, Ciccarelli A, Zarrilli S, Guerra E, Gaccione M, Di Sarno A, Lombardi G, Colao A (2006) The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol (Oxford) 64:307\u2013313. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02461.x","journal-title":"Clin Endocrinol (Oxford)"},{"key":"1259_CR11","doi-asserted-by":"publisher","first-page":"dgaa650","DOI":"10.1210\/clinem\/dgaa650","volume":"105","author":"M Sehemby","year":"2020","unstructured":"Sehemby M, Lila AR, Sarathi V, Shah R, Sankhe S, Jaiswal SK, Ramteke-Jadhav S, Patil V, Shah N, Bandgar T (2020) Predictors of chronic LH-testosterone axis suppression in male macroprolactinomas with normoprolactinemia on cabergoline. J Clin Endocrinol Metab 105:dgaa650. https:\/\/doi.org\/10.1210\/clinem\/dgaa650","journal-title":"J Clin Endocrinol Metab"},{"key":"1259_CR12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11102-010-0251-6","volume":"14","author":"I Shimon","year":"2011","unstructured":"Shimon I, Benbassat C, Tzvetov G, Grozinsky-Glasberg S (2011) Anemia in a cohort of men with macroprolactinomas: increase in hemoglobin levels follows prolactin suppression. Pituitary 14:11\u201315. https:\/\/doi.org\/10.1007\/s11102-010-0251-6","journal-title":"Pituitary"},{"key":"1259_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1365-2265.1982.tb03159.x","volume":"16","author":"PJ Moult","year":"1982","unstructured":"Moult PJ, Rees LH, Besser GM (1982) Pulsatile gonadotrophin secretion in hyperprolactinaemic amenorrhoea an the response to bromocriptine therapy. Clin Endocrinol (Oxford) 16:153\u2013162. https:\/\/doi.org\/10.1111\/j.1365-2265.1982.tb03159.x","journal-title":"Clin Endocrinol (Oxford)"},{"key":"1259_CR14","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1007\/s12020-015-0791-7","volume":"52","author":"E Espinosa","year":"2016","unstructured":"Espinosa E, Sosa E, Mendoza V, Ram\u00edrez C, Melgar V, Mercado M (2016) Giant prolactinomas: are they really different from ordinary macroprolactinomas? Endocrine 52:652\u2013659. https:\/\/doi.org\/10.1007\/s12020-015-0791-7","journal-title":"Endocrine"},{"issue":"96","key":"1259_CR15","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"2011","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011(96):273\u2013288. https:\/\/doi.org\/10.1210\/jc.2010-1692","journal-title":"J Clin Endocrinol Metab"},{"key":"1259_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrendo.2011.37","volume":"7","author":"A Colao","year":"2011","unstructured":"Colao A, Savastano S (2011) Medical treatment of prolactinomas. Nat Rev Endocrinol 7:267\u2013278. https:\/\/doi.org\/10.1038\/nrendo.2011.37","journal-title":"Nat Rev Endocrinol"},{"key":"1259_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/cen.12124","volume":"79","author":"N Karavitaki","year":"2013","unstructured":"Karavitaki N, Dobrescu R, Byrne JV, Grossman AB, Wass JA (2013) Does hypopituitarism recover when macroprolactinomas are treated with cabergoline? Clin Endocrinol (Oxford) 79:217\u2013223. https:\/\/doi.org\/10.1111\/cen.12124","journal-title":"Clin Endocrinol (Oxford)"},{"key":"1259_CR18","first-page":"314","volume":"134","author":"R Walia","year":"2011","unstructured":"Walia R, Bhansali A, Dutta P, Khandelwal N, Sialy R, Bhadada S (2011) Recovery pattern of hypothalamo-pituitary-testicular axis in patients with macroprolactinomas after treatment with cabergoline. Indian J Med Res 134:314\u2013319","journal-title":"Indian J Med Res"},{"key":"1259_CR19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1365-2265.2006.02627.x","volume":"65","author":"N Karavitaki","year":"2006","unstructured":"Karavitaki N, Thanabalasingham G, Shore HC et al (2006) Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol (Oxford) 65:524\u2013529. https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02627.x","journal-title":"Clin Endocrinol (Oxford)"},{"issue":"Suppl 1","key":"1259_CR20","doi-asserted-by":"publisher","first-page":"A632","DOI":"10.1210\/jendso\/bvab048.1289","volume":"5","author":"M Voica","year":"2021","unstructured":"Voica M, Tetlay M, Thompson DV, Hasan F (2021) Recovery of male hypogonadism following successful treatment of prolactinoma: the experience of an integrated health network. J Endocr Soc 5(Suppl 1):A632. https:\/\/doi.org\/10.1210\/jendso\/bvab048.1289","journal-title":"J Endocr Soc"},{"key":"1259_CR21","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1055\/a-0752-0741","volume":"50","author":"P Iglesias","year":"2018","unstructured":"Iglesias P, Arcano K, Berrocal VR, Bernal C, Villabona C, D\u00edez JJ (2018) Giant prolactinoma in men: clinical features and therapeutic outcomes. Horm Metab Res 50:791\u2013796. https:\/\/doi.org\/10.1055\/a-0752-0741","journal-title":"Horm Metab Res"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01259-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-022-01259-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01259-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T10:49:49Z","timestamp":1668854989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-022-01259-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1259"],"URL":"https:\/\/doi.org\/10.1007\/s11102-022-01259-3","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]},"assertion":[{"value":"8 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}